Imipenem + Cilastatin Aptapharma (Cilastatin, Imipenem)

Imipenem, the active ingredient in Imipenem + Cilastatin Aptapharma, is a carbapenem antibiotic presented as an injection solution for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, nosocomial pneumonia, skin and soft tissue infections, and septicemia in hospitalized patients.

GNH USA supplies Imipenem + Cilastatin Aptapharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Imipenem/cilastatin is a carbapenem antibiotic used to treat serious bacterial infections affecting various organ systems.

Complicated intra‑abdominal infections: eradicates mixed aerobic and anaerobic pathogens to resolve infection. Complicated urinary tract infections: provides rapid bactericidal activity against resistant uropathogens. Nosocomial pneumonia: treats hospital‑acquired lung infections caused by Gram‑negative and Gram‑positive bacteria. Skin and soft tissue infections: eliminates causative bacteria in severe cellulitis and wound infections. Septicemia: offers broad‑spectrum coverage for bloodstream infections.

Adverse reactions to Imipenem/cilastatin may vary in frequency and severity.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, sometimes due to altered gut flora. - Rash: mild skin erythema or pruritus. - Injection site pain: discomfort at the IV site. - Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: severe allergic reaction with hives, airway swelling. - Stevens‑Johnson syndrome: rare mucocutaneous blistering disorder.

Clinicians should consider several precautions when prescribing Imipenem/cilastatin.

Renal function: adjust dose in patients with impaired kidney function. Seizure risk: avoid or monitor in patients with a history of seizures or CNS disorders. Hypersensitivity: assess for allergy to β‑lactams before use. Concomitant valproic acid: monitor serum levels as imipenem may reduce valproate concentrations. Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Imipenem/cilastatin can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: co‑administration can markedly reduce valproate levels, risking seizure breakthrough. - Carbapenem antibiotics with other β‑lactams: may increase risk of additive toxicity or antagonism.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): may enhance nephrotoxic potential, monitor renal function. - Probenecid: can increase plasma concentrations of imipenem, adjust dose if needed. - Anticoagulants (warfarin): may alter INR, require closer monitoring.